Evotec SE (LTS:0IRF) Total Liabilities : €960.0 Mil (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Evotec SE Total Liabilities?

Evotec SE's Total Liabilities for the quarter that ended in Dec. 2024 was €960.0 Mil.

Evotec SE's quarterly Total Liabilities increased from Jun. 2024 (€987.43 Mil) to Sep. 2024 (€1,022.34 Mil) but then declined from Sep. 2024 (€1,022.34 Mil) to Dec. 2024 (€959.98 Mil).

Evotec SE's annual Total Liabilities increased from Dec. 2022 (€1,070.06 Mil) to Dec. 2023 (€1,132.56 Mil) but then declined from Dec. 2023 (€1,132.56 Mil) to Dec. 2024 (€959.98 Mil).

Evotec SE Total Liabilities Historical Data

The historical data trend for Evotec SE's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Total Liabilities Chart

Evotec SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

737.88

857.48

1,070.06

1,132.56

959.98

Evotec SE Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															1,132.56	1,102.14	987.43	1,022.34	959.98

Evotec SE Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Evotec SE's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	344.585	+	(392.743	+	20.897
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	201.752	+	0	+	0)
	=	960.0

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	1912.502	-	952.525
	=	960.0

Evotec SE's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	344.585	+	(392.743	+	20.897
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	201.752	+	0	+	0)
	=	960.0

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	1912.502	-	952.525
	=	960.0

Evotec SE Total Liabilities Related Terms

Thank you for viewing the detailed overview of Evotec SE's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Evotec SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (LTS:0IRF) » Definitions » Total Liabilities

Traded in Other Exchanges

EVO:USA 1EVT:Italy EVTd:UK EVT:Germany EVT:Bulgaria EVT:Austria

Address

Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419

Website

https://www.evotec.com

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Evotec SE Headlines

No Headlines